

ANNUAL HEALTH INSURANCE TREATMENT COST OF POLYCYSTIC OVARY SYNDROME BASED ON REAL-WORLD HEALTH INSURANCE CLAIMS DATA

Kovács D^{2,3}, Endrei D², Csákvári T¹, Elmer D², Kajos LF^{2,3}, Pónusz R², Molics B², Boncz F².
 1.University of Pécs, Zalaegerszeg, Hungary, 2. University of Pécs, Pécs, Hungary, Doctoral School of Health Sciences, Faculty of Health Sciences, 3.University of Pécs, Pécs, Hungary

OBJECTIVES

Polycystic ovary syndrome (PCOS) is a highly prevalent disorder, representing the single most common endocrine-metabolic disorder in reproductive-aged women. Our aim was to determine the annual health insurance treatment cost of polycystic ovary syndrome in Hungary.

METHODS

Data were derived from the financial database of the Hungarian National Health Insurance Fund Administration of the year 2019. The database included annual health insurance costs, number of patients and financed costs distribution calculated for age groups. The following cost categories were included into the study: general practice care, home care, in- and outpatient care, medical imaging, laboratory diagnostics, pharmaceuticals and medical aids. Patients with polycystic ovary syndrome were identified with the following code of the International Classification of Diseases 10th revision: E2820.

RESULTS

In 2019, the NHIFA spent 128.40 million Hungarian Forints (HUF) for the treatment of patients with PCOS, 441,787 American Dollars (USD), or 394,669 Euros (EUR). The highest number of patients were in outpatient care (12,834 women). Outpatient care (40.0 % of total health insurance costs), utilization of general practice care (26.6%) and laboratory diagnostics (15.5%) were the main cost drivers, while all other forms of medical care amounted to 17.7% in women. Annual health care treatment costs per patient were 9.992 HUF (34 USD/31 EUR) according to number of patients related to outpatient care. The highest annual health insurance costs were found in the '20-29' age group.

CONCLUSIONS

The utilization of outpatient care was the major cost driver, which was 1.5 times higher than the utilization of general practice care and 10.14 times as higher as pharmaceuticals costs in 2019. The proportion of the costs related to the treatment didn't show significant differences among age groups.

TYPE OF CARE	NUMBER OF PATIENTS	NUMBER OF CASES
GENERAL PRACTICIONER	6,876	17,044
PATIENT TRANSPORTATION	1	3
OUTPATIENT CARE	12,832	27,762
CAREGIVER SERVICES	17	59
LABORATORY DIAGNOSTICS	4,287	6,998
CT	103	173
INPATIENT CARE	86	87
CHRONIC INPATIENT CARE	0	0
PHARMACEUTICALS	3,178	7,700

Table 1. Annual utilization of Polycystic ovary syndrome (PCOS) treatment in Hungary in 2019.




Figure 1. The characteristics of the expenditure related to the Polycystic ovary syndrome (PCOS) treatment in Hungary




Figure 2. Distribution of the annual health insurance treatment cost of Polycystic ovary syndrome (PCOS) in Hungary according to type of the care in 2019.




Figure 3. Distribution of the annual health insurance treatment cost of Polycystic ovary syndrome (PCOS) in Hungary according to type of care in 2019.

ISPOR 2022
 May 15-18, 2022
 Washington, DC, USA Area and Virtual

PÉCSI TUDOMÁNYEGYETEM
 UNIVERSITY OF PÉCS

Funding:
 The research was financed by the National Laboratory for Human Reproduction (HRNL) established under the leadership of the University of Pécs.

Corresponding author:
 Dalma Kovács, MS.c
 University of Pécs, Faculty of Health Sciences, Hungary
 Institute for Health Insurance
 E-mail: dalma.kovacs@etk.pte.hu

EE 445

SZÉCHENYI 2020

HUNGARIAN GOVERNMENT

European Union
 European Social Fund

INVESTING IN YOUR FUTURE